Prime Medicine, Inc. (PRME), a biotechnology company, on Friday announced that it has appointed Allan Reine as its new chief financial officer, effective January 17.Reine takes over from interim CFO and Chief Accounting Officer Carman Alenson.Allan Reine was the finance chief of Foghorn Therapeutics and at Pieris Pharmaceuticals previously.In pre-market activity, Prime Medicine shares are trading at $9.07, up 0.67% on the Nasdaq.

生物技术公司Prime Medicine，Inc.（PRME）周五宣布，已任命艾伦·雷恩（AllanReine）为新任首席财务官，自1月17日起生效。雷恩接替临时首席财务官兼首席会计官卡曼·阿伦森（CarmanAlenson）。艾伦·雷恩（AllanReine）此前是福格霍恩治疗公司（Foghorn Therapeutics）和皮耶利斯制药公司（Pieris Pharmaceuticals）的财务总监。在上市前活动中，Prime Medicine股票在纳斯达克的交易价格为9.07美元，上涨0.67%。

For comments and feedback contact: editorial@rttnews.comBusiness News.

如需评论和反馈，请联系：editorial@rttnews.comBusiness新闻。

Biotech Stocks Facing FDA Decision In November 2023

2023年11月美国食品和药物管理局（FDA）决定生物技术股

Biotech Stocks Facing FDA Decision In October 2023

2023年10月美国食品和药物管理局（FDA）决定生物技术股

Biotech Stocks Facing FDA Decision in August 2023

2023年8月美国食品和药物管理局（FDA）决定生物技术股